ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
ADC Therapeutics has raised $86.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
ADC Therapeutics's investors include TCG Crossover, AstraZeneca, Redmile Group, Bain Capital Life Sciences, 4BIO Capital.
ADC Therapeutics is headquartered in Lausanne, Switzerland.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
ADC Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ADC Therapeutics — Funding & Investors." VCBacked, October 8, 2026, https://www.vcbacked.co/company/adc-therapeutics. Accessed November 15, 2026.
VCBacked. (2026). ADC Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/adc-therapeutics
{{cite web |title=ADC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adc-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ADC Therapeutics? Request a listing update